BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9111422)

  • 21. Unbalanced 6p translocation as primary karyotypic anomaly in secondary acute nonlymphocytic leukemia.
    Mancini M; Mecucci C; Cedrone M; Rondinelli MB; Aloe-Spiriti MA; Alimena G
    Cancer Genet Cytogenet; 1992 May; 60(1):93-5. PubMed ID: 1591714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytogenetic study in therapy-related myelodysplastic syndromes (t-MDS) and acute non-lymphocytic leukaemia (t-ANLL).
    Sozzi G; Miozzo M; Orazi A; Calderone C; Castellano M; Viviani S; Santoro A; Pierotti MA; Della Porta G
    Br J Cancer; 1990 Mar; 61(3):425-8. PubMed ID: 2328210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Secondary leukemia following treatment of Hodgkin's disease: ultrastructural and cytogenetic data in two cases with a review of the literature.
    Yahalom J; Voss R; Leizerowitz R; Fuks Z; Polliack A
    Am J Clin Pathol; 1983 Aug; 80(2):231-6. PubMed ID: 6349327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early-stage Hodgkin's disease: long-term results with radiotherapy alone or combined radiotherapy and chemotherapy.
    Brusamolino E; Lazzarino M; Orlandi E; Canevari A; Morra E; Castelli G; Alessandrino EP; Pagnucco G; Astori C; Livraghi A
    Ann Oncol; 1994; 5 Suppl 2():101-6. PubMed ID: 7515642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies.
    Darrington DL; Vose JM; Anderson JR; Bierman PJ; Bishop MR; Chan WC; Morris ME; Reed EC; Sanger WG; Tarantolo SR
    J Clin Oncol; 1994 Dec; 12(12):2527-34. PubMed ID: 7989926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group.
    Schellong G; Riepenhausen M; Creutzig U; Ritter J; Harbott J; Mann G; Gadner H
    J Clin Oncol; 1997 Jun; 15(6):2247-53. PubMed ID: 9196137
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Occurrence of acute nonlymphocytic leukemia in a prospective randomized study of treatment for Hodgkin's disease.
    Gomez GA; Friedman M; Reese P
    Am J Clin Oncol; 1983 Jun; 6(3):319-23. PubMed ID: 6342359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Combined treatment strategy in over 200 children with Hodgkin's disease: graduated chemotherapy, involved field irradiation with low dosage and selective splenectomy. A report of the cooperative therapy study DAL-HD-82].
    Schellong G; Brämswig J; Ludwig R; Gerein V; Jobke A; Jürgens H; Kabisch H; Stollmann B; Weinel P; Gadner H
    Klin Padiatr; 1986; 198(3):137-46. PubMed ID: 3523020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erythrocyte mean corpuscular volume during cytotoxic therapy is a predictive parameter of secondary leukemia in Hodgkin's disease.
    de Gramont A; Louvet C; Krulik M; Smadja N; Donadio D; Laporte JP; Brissaud P; Delâge JM; Drolet Y; Rioux E
    Cancer; 1987 Jan; 59(2):301-4. PubMed ID: 3467821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence of second cancers in patients treated for Hodgkin's disease.
    Boivin JF; Hutchison GB; Zauber AG; Bernstein L; Davis FG; Michel RP; Zanke B; Tan CT; Fuller LM; Mauch P
    J Natl Cancer Inst; 1995 May; 87(10):732-41. PubMed ID: 7563150
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of stages I and II Hodgkin's disease with three different therapeutic modalities.
    Koziner B; Myers J; Cirrincione C; Redman J; Cunningham I; Caravelli J; Nisce LZ; McCormick B; Straus DJ; Mertelsmann R
    Am J Med; 1986 Jun; 80(6):1067-78. PubMed ID: 3755285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Secondary malignancies in a child with Hodgkin's disease: T-cell lymphoma and myelodysplastic syndrome evolving into acute nonlymphoblastic leukaemia.
    Polychronopoulou S; Panagiotou JP; Papadakis T; Mavrou A; Anagnostou D; Haidas S
    Med Pediatr Oncol; 1996 May; 26(5):359-66. PubMed ID: 8614370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased risk of lung cancer, non-Hodgkin's lymphoma, and leukemia following Hodgkin's disease.
    van Leeuwen FE; Somers R; Taal BG; van Heerde P; Coster B; Dozeman T; Huisman SJ; Hart AA
    J Clin Oncol; 1989 Aug; 7(8):1046-58. PubMed ID: 2754447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Second neoplasms in patients with Hodgkin's disease following combined modality therapy--the Yale experience.
    Koletsky AJ; Bertino JR; Farber LR; Prosnitz LR; Kapp DS; Fischer D; Portlock CS
    J Clin Oncol; 1986 Mar; 4(3):311-7. PubMed ID: 3950674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Second malignant tumours in childhood Hodgkin's disease.
    Jenkin D; Greenberg M; Fitzgerald A
    Med Pediatr Oncol; 1996 Jun; 26(6):373-9. PubMed ID: 8614372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: eight-year update of an Italian prospective randomized study.
    Biti GP; Cimino G; Cartoni C; Magrini SM; Anselmo AP; Enrici RM; Bellesi GP; Bosi A; Papa G; Giannarelli D
    J Clin Oncol; 1992 Mar; 10(3):378-82. PubMed ID: 1740677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma.
    Stone RM; Neuberg D; Soiffer R; Takvorian T; Whelan M; Rabinowe SN; Aster JC; Leavitt P; Mauch P; Freedman AS
    J Clin Oncol; 1994 Dec; 12(12):2535-42. PubMed ID: 7989927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute nonlymphocytic leukemia after radiation and MOPP chemotherapy for Hodgkin's disease.
    Lavey RS
    J Clin Oncol; 1990 Dec; 8(12):2089-90. PubMed ID: 2230901
    [No Abstract]   [Full Text] [Related]  

  • 39. The risk of second malignant tumors and its consequences for the overall survival of Hodgkin's disease patients and for the choice of their treatment at presentation: analysis of a series of 1524 cases consecutively treated at the Florence University Hospital.
    Cellai E; Magrini SM; Masala G; Alterini R; Costantini AS; Rigacci L; Olmastroni L; Papi MG; Spediacci MA; Innocenti F; Bellesi G; Ferrini PR; Biti G
    Int J Radiat Oncol Biol Phys; 2001 Apr; 49(5):1327-37. PubMed ID: 11286841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
    Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.